Sepsis is a severe and potentially fatal syndrome that arises when the body mounts a dysregulated immune response to infection, leading to widespread organ dysfunction. The immune system, instead of effectively fighting the infection, becomes overactive and then weakened, contributing to severe complications and high mortality rates. This progression makes sepsis one of the leading causes of death in intensive care units worldwide.

One of the key consequences of sepsis is immunosuppression, where the body’s ability to defend itself is significantly reduced. This condition leads to a depletion and dysfunction of immune cells, including T cells, which are crucial for combating infections. The impaired immune system renders patients vulnerable to secondary infections, prolonged hospital stays, and increased mortality. Addressing this weakened immune state has become a primary focus of clinical research, with immunomodulatory treatments being explored as complementary therapies to antibiotics in the management of sepsis.

Thymosin α1 in Immune Modulation

Thymosin α1, a peptide hormone secreted by the thymus, has gathered attention for its ability to regulate immune responses. It has a significant role in immune cell differentiation, maturation, and activation. Studies have demonstrated its potential to mitigate immune system damage caused by chemotherapy, enhance dendritic cell function to improve antifungal responses, and reduce T cell exhaustion, which is critical in reversing lymphopenia. These properties make thymosin α1 a promising candidate for immune restoration in patients with sepsis-induced immunosuppression.

Thymosin α1 has been widely used in various medical conditions, including non-small cell lung cancer, melanoma, chronic hepatitis, AIDS, COVID-19, and sepsis. Its broad immunomodulatory effects suggest it may have a role in restoring immune function in sepsis patients, making it a subject of interest in recent clinical trials. However, the effectiveness of thymosin α1 in reducing mortality and improving immune response in sepsis patients remains an area of ongoing research.

Evidence from Previous Research

Research has indicated that thymosin α1 might enhance immune function and lower mortality in sepsis patients. Clinical observations suggested that it could restore immune balance, increase the production of immune cells, and improve the body’s ability to combat infections. A meta-analysis of ten randomised controlled trials, encompassing 530 patients, suggested that the peptide could reduce 28-day mortality by 41%. However, despite these encouraging findings, the reliability of the evidence was limited due to the small sample sizes, lack of standardised protocols, and methodological inconsistencies across studies.

Insights from the TESTS Clinical Trial

To address the limitations of previous studies, the TESTS trial, officially named The Efficacy and Safety of Thymosin α1 for Sepsis, was conducted as a multicentre, randomised, double-blinded, placebo-controlled study. This trial aimed to provide more definitive evidence regarding the role of thymosin α1 in sepsis treatment. The study enrolled a significantly larger cohort of patients compared to prior research, making its findings more robust and generalisable.

Despite its rigorous design, the TESTS trial did not find conclusive evidence that thymosin α1 significantly reduced 28-day mortality in adult sepsis patients. The results indicated that there was no statistically significant difference between the thymosin α1 group and the placebo group in terms of survival rates. However, the trial confirmed that thymosin α1 has a strong safety profile, demonstrating that it does not pose additional risks to patients undergoing sepsis treatment.

Nevertheless, certain subgroups of patients, particularly those aged 60 and older or with chronic conditions such as diabetes, hypertension, and coronary heart disease, exhibited potential benefits from the treatment. These findings suggest that thymosin α1 may be more effective in-patient populations with compromised immune function, warranting further exploration of its targeted use.

Comparing the TESTS Trial with Prior Studies

Earlier trials faced notable methodological challenges, such as small participant numbers, lack of blinding, and imbalances in patient characteristics. In light of the heterogeneous nature of sepsis, finding a single drug that significantly improves survival rates has proven difficult. This variability complicates the evaluation of treatment efficacy and highlights the need for stratified approaches in clinical research.

The TESTS trial nearly doubled the sample size of previous studies, yet it still faced challenges in demonstrating a clear mortality benefit. Additionally, issues related to dosage selection may have influenced outcomes, as higher doses have shown efficacy in other research contexts. The possibility that an insufficient dosage of thymosin α1 was administered in the trial suggests that future studies should explore optimised dosing regimens to maximise potential benefits.

Clinical Implications of Thymosin α1

Age and chronic illnesses play a crucial role in immune function and response to sepsis treatment. Thymosin α1 appears to be more effective in older adults and those with underlying chronic conditions, suggesting that it may help counteract the immune dysfunction associated with aging and comorbidities. As immune systems weaken with age and chronic disease, thymosin α1 could serve as an adjunct therapy to strengthen immune responses and improve patient outcomes.

A major factor in sepsis-related immunosuppression is T cell exhaustion, which impairs the body’s ability to combat infections effectively. Thymosin α1’s role in reducing this exhaustion may provide a pathway for improving patient outcomes in select populations. However, its lack of widespread efficacy in younger and otherwise healthy patients indicates that its utility may be limited to specific groups rather than as a universal treatment for sepsis.

Biomarkers and the Immune Response in Sepsis

Assessing immune function in sepsis patients often involves measuring specific biomarkers that indicate the state of immune activation and suppression. Key biomarkers include monocyte human leukocyte antigen-DR (HLA-DR) expression, regulatory T cell percentage, lymphocyte count, and the neutrophil-to-lymphocyte ratio. These markers help evaluate the severity of immune suppression and guide treatment strategies.

The TESTS trial found improvements in immune markers in both the thymosin α1 and placebo groups. However, the reduction in the neutrophil-to-lymphocyte ratio was more pronounced with thymosin α1, suggesting that it plays a role in maintaining immune homeostasis. This finding supports the idea that thymosin α1 has immunoregulatory properties that may be beneficial in managing sepsis-related immune dysfunction.

Challenges and Limitations

One of the primary challenges in sepsis research is its heterogeneous nature, making it difficult to achieve consistent treatment outcomes across diverse patient groups. The ambitious sample size assumptions of the TESTS trial may have contributed to underpowering the study, limiting its ability to detect smaller, yet potentially meaningful, benefits of thymosin α1.

Another challenge lies in the timing of treatment. Many patients were not in the early stages of sepsis when they received thymosin α1, potentially affecting efficacy. Additionally, laboratory inconsistencies in measuring monocyte HLA-DR levels could have obscured real treatment effects. Variability in sepsis progression also makes it difficult to apply a one-size-fits-all approach to treatment, necessitating further research on individualised therapeutic strategies.

Conclusion

While the TESTS trial does not provide strong evidence supporting thymosin α1 as a mortality-reducing treatment for sepsis, its potential benefits in older adults and patients with chronic conditions merit further investigation. Future research should focus on optimising dosage, targeting specific patient subgroups, and standardising immune biomarker assessments to better understand the clinical value of thymosin α1 in sepsis management.

As sepsis remains a complex and multifaceted condition, continued exploration of immunomodulatory therapies like thymosin α1 may contribute to more effective and personalised treatment strategies in the future. The identification of specific patient groups who benefit most from thymosin α1 will be crucial in determining its place in clinical practice. Further large-scale, well-designed trials will be necessary to clarify its role and refine its application in sepsis care.

Wu, J., Pei, F., Zhou, L., Li, W., Sun, R., Li, Y., Wang, Z., He, Z., Zhang, X., Jin, X., Long, Y., Cui, W., Wang, C., Chen, E., Zeng, J., Yan, J., Lin, Q., Zhou, F., Huang, L., … TESTS study collaborator group. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ (Clinical Research Ed.), 388, e082583. https://doi.org/10.1136/bmj-2024-082583

Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-9. doi:10.1182/ blood-2003-11-4036

Yu K, He J, Wu Y, et al. Dysregulated adaptive immune response contributes to severe COVID-19. Cell Res 2020;30:814-6. doi:10.1038/s41422-020-0391-9

Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis 2020;71:2150-7. doi:10.1093/cid/ciaa630

Maio M, Mackiewicz A, Testori A, et al, Thymosin Melanoma Investigation Group. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010;28:1780-7. doi:10.1200/JCO.2009.25.5208

Chen C, Wang J, Xun J, et al. Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV. BMC Infect Dis 2024;24:97. doi:10.1186/s12879-024-08985-y

Liu F, Wang HM, Wang T, Zhang YM, Zhu X. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis 2016;16:488. doi:10.1186/s12879-016-1823-5